Slovenia Pharmaceuticals & Healthcare Report

Published 20 February 2015

  • 95 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Slovenia Pharmaceuticals & Healthcare Report

BMI View: Positive economic developments in the eurozone and increasing competitiveness due to euro depreciation should boost demand for Slovenian pharmaceutical exports. It is also likely that economic pickup in Slovenia will push demand for pharmaceutical imports. The Slovenian pharmaceutical industry's focus on generic drugs will be beneficial given the developing trend for greater generic penetration in Europe and the demand for low-cost medicines in emerging markets.

Headline Expenditure Projections

  • Pharmaceuticals: EUR675mn (USD896mn) in 2014 to EUR671mn (USD738mn) in 2015; -0.6% in local currency terms and -17.6% in US dollar terms. Forecasts lowered compared to previous quarter.

  • Healthcare: EUR3.22bn (USD4.27bn) in 2014 to EUR3.23bn (USD3.55bn) in 2015; 0.4% in local currency terms and -16.8% in US dollar terms. Forecasts increased compared to previous quarter.

BMI Risk/Reward Index

Slovenia scores 51.6 out of a total of 100 in our Pharmaceutical Risk/Reward Index for Q315 - up from 50.4 in the previous quarter. This places the country 8th in our index of 20 countries and above the average for the region, which is 49.5.

Key Trends & Developments

  • Slovenian generic pharmaceutical company Krka recorded a 4% decline in net profit to EUR166.2mn (USD185.7mn) in 2014, compared with EUR172.7mn (USD193mn) in 2013, reports Reuters. Sales fell to EUR1.19bn (USD1.33bn) in 2014, compared with EUR1.20bn (USD1.34bn) in 2013. Krka expects sales to reach EUR1.26bn (USD1.41bn) in 2015, with sales outside Slovenia expected to represent 94% of total sales. The company expects net profit in 2015 to remain at similar levels to 2014.

  • Healthcare investor and entrepreneur, Joseph Priel and private equity firm, ARX Partners, have purchased Slovenian hospital DCB (Diagnostic Centre Bled) from family owners. This is believed to be the first big private healthcare services deal in the country. Priel's businesses are now active in at least four countries, reports...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovenia 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2010-2018)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2010-2018)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovenia 2010-2018)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovenia 2010-2018)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovenia 2010-2018)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovenia 2010-2018)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Slovenia 2012-2018)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovenia 2012-2018)
28
Key Risks To BMI's Forecast Scenario
29
Macroeconomic Forecasts
31
Economic Analysis
31
Real GDP By Expenditure Breakdown
32
Risks To Outlook
34
Table: Economic Activity (Slovenia 2009-2018)
34
Industry Risk Reward Ratings
35
Central And Eastern Europe Risk/Reward Ratings
35
Slovenia Risk/Reward Ratings
42
Rewards
42
Risks
42
Market Overview
44
Industry Trends And Developments
46
Epidemiology
46
Healthcare Sector
47
Research & Development
50
Regulatory Development
51
Intellectual Property Regime
52
Pricing Regime
52
Reimbursement Regime
54
Competitive Landscape
56
Pharmaceutical Industry
56
Recent Pharmaceutical Industry Developments
57
Company Profile
59
Krka
59
Lek (Novartis/Sandoz)
65
GlaxoSmithKline (GSK)
69
Sanofi
72
Pfizer
74
Novartis
77
Merck & Co
79
Demographic Forecast
81
Table: Slovenia's Population By Age Group, 1990-2020, 1990-2020 ('000)
82
Table: Slovenia's Population By Age Group, 1990-2020 (% of total)
83
Table: Slovenia's Key Population Ratios, 1990-2020
84
Table: Slovenia's Rural And Urban Population, 1990-2020
84
Glossary
85
Methodology
87
Pharmaceutical Expenditure Forecast Model
87
Healthcare Expenditure Forecast Model
87
Notes On Methodology
88
Risk/Reward Index Methodology
89
Index Overview
90
Table: Pharmaceutical Risk/Reward Index Indicators
90
Indicator Weightings
91

The Slovenia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Slovenia, to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Slovenian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovenia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc